科伦博泰芦康沙妥珠单抗国内获批上市 系首个获得完全批准上市的国产ADC药物

每日经济新闻
27 Nov 2024

每经记者:陈星    每经编辑:董兴生11月27日,科伦博泰生物-B(HK06990,股价196港元,市值436.77亿港元)宣布,公司首款针对既往至少接受过2种系统治疗的不可切除的局部晚期或转移性三阴性乳腺癌成人患者的国产靶向人滋养细胞表面抗原2(TROP2)的抗体药物偶联物(ADC)芦康沙妥珠单抗获国家药品监督管理局批准在中国上市。据科伦博泰新闻稿,这是首个国产TROP2 ADC在中国获批上市...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10